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Abstract
Introduction: The objective of this study was to evaluate glucose transport into lymphocytes in healthy subjects and patients
with type 2 diabetes mellitus (DM) treated either with diet only or with insulin and to propose peripheral blood lymphocytes
as a convenient model for cellular glucose transport studies. 
Materials and Methods: Sixty subjects with type 2 DM, 30 treated with diet only and 30 with insulin, were investigated. Thirty
healthy subjects matched for age, weight, and sex served as a control group. Deoxy-D-glucose, 2-[3H(G)] transport was stud-
ied in isolated peripheral blood lymphocytes. Expression of glucose transporters was ascertained by immunocytochemical
identification and by Western blotting.
Results: In lymphocytes from the control group, deoxy-D-glucose uptake increased gradually with the duration of the exper-
iment. In diabetics treated with insulin, the maximal increase in deoxy-D-glucose uptake was observed after 30 min of the
investigation, followed by a plateau phase. In diabetics treated with diet, deoxy-D-glucose uptake increased slowly during the
first 30 min. The presence of GLUT1 and GLUT3 in lymphocytes was confirmed in this study.
Conclusions: Glucose transport into lymphocytes is altered in type 2 DM. In lymphocytes from diabetics, the dynamics of
deoxy-D-glucose uptake significantly differed from that in healthy subjects. There was also a significant difference between
the diabetic groups, representing different modes of therapy and stages of the disease. Glucose transport into lymphocytes
is apparently influenced by DM as well as by the mode of therapy. We suggest that peripheral blood lymphocytes may
become a promising model for studies on glucose transport in diabetes.
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INTRODUCTION
Glucose transport defects in diabetes mellitus (DM)
lead to the impairment of the rate of glucose utilization by
peripheral tissues. The first step of this complex process is
cellular glucose transport, the properties of which in
peripheral blood lymphocytes of diabetic patients are
not known and information on glucose transporters in
these cells is scarce and inconsistent. Moreover, inade-
quate metabolism of glucose in these cells is the reason
for the significant impairment of their function. So far,
a number of studies have focused on glucose transport
under various metabolic conditions. These studies, how-
ever, concerned almost exclusively the classically
defined insulin-dependent tissues, i.e. muscle and adi-
pose tissue [2, 13, 20]. There are also data available on
glucose transport into pancreatic islet B cells [15, 16].
The first stage of glucose metabolism is its entry
into cells by means of facilitated diffusion in the direc-
tion of a glucose concentration gradient. The glucose
transport facilitators are proteins of the GLUT family.
These are widely distributed proteins present in the
plasma membranes of almost all cells. In human cells
and tissues there are several isoforms of these trans-
porters: GLUT1 to 12 and HMIT1, encoded by distinct
genes of the SLC2A family (a HUGO Gene
Nomenclature Committee approved symbol) [17, 42].
The expression of particular genes of the SLC2A fami-
ly, including the newest member of the GLUT family,
GLUT14 [43], is specific to tissues and cells [4, 10, 23,
25, 32, 33, 36, 38]. Early studies on glucose transport
into lymphocytes suggested the presence of a system of
facilitated diffusion in these cells [31]. Several studies
revealed that GLUTl and GLUT3 are present as glu-cose transporter proteins in lymphocytes [7, 11, 23].
Pathological changes in serum glucose concentration
influence SLC2A gene expression, glucose uptake, and
glucose metabolism in lymphocytes [26]. Sustained
hypoglycemia effects SLC2A gene expression of human
blood leukocytes, especially in granulocytes and mono-
cytes. In granulocytes the level of GLUT4 increases by
73%, whereas a reduction in GLUT1 and a rise in
GLUT3 is observed. On the other hand, the majority of
the lymphocyte population was found to be negative for
these carriers [21]. 
Clinical observations and laboratory findings suggest
that lymphocytes may function abnormally in DM [5, 28,
37, 40]. An increased susceptibility to infections is a well-
-known complication of a poorly controlled diabetic
state [18, 28, 39, 41]. In diabetic patients, infections take
a more severe course and complications occur more
often. Studies have shown that diabetes is a pathological
state that influences immunity. Available publications
concern altered properties of leukocytes, chemotaxis,
adherence, and phagocytosis that are crucial elements in
immune response [9, 12, 40]. Nonetheless, scientific evi-
dence in this field of study is not abundant and relates
mainly to polymorphonuclear leukocytes. There are
some data on lymphocyte function in animal studies. In
alloxan-induced diabetic rats and in obese rats with
impaired glucose tolerance, decreased mitogen response
of lymphocytes has been observed [27, 29]. 
Glucose is the most important energy source for
cells with high energy consumption. This is the case for
lymphocytes, which must react rapidly in response to
pathogens. Altered glucose metabolism was shown to be
responsible for low lymphocyte proliferation in response
to mitogen [29]. Glucose transport seems to be a crucial
step in this process. Its pathological changes may con-
tribute to the altered lymphocyte status observed in
DM. However, leukocyte functions that are not directly
related to immune response have seldom been studied
in diabetic patients [7, 35]. 
It was shown that in mononuclear cells from
patients with type 1 diabetes, 2-deoxyglucose uptake
increased in response to insulin in vitro in comparison
with nondiabetic subjects. This was observed only in the
monocyte population [7]. Monocytes have the capacity
to specifically bind insulin. This was not shown in the
case of lymphocytes, but both types of cells have
insulin-degrading activity [35]. Diabetes also causes
important changes in lymphocyte metabolism [30]. In
lymphocytes of patients with type 2 diabetes, the activi-
ty of pyruvate dehydrogenase is lower in comparison
with healthy subjects [6, 28]. 
It is still not known how deoxy-D-glucose transport
is altered in lymphocytes from patients with type 2 dia-
betes and what transporters are actually present in the
lymphocyte membranes. Some contradictory data on
glucose transport in lymphocytes and the importance of
these cells in the pathological conditions associated with
DM were the major reasons to focus on lymphocytes in
our study. Glucose transport defects in diabetes could
be conveniently studied in human subjects using blood
cell types such as lymphocytes. The aim of this study was
an evaluation of deoxy-D-glucose transport into lym-
phocytes in healthy subjects and in patients with type 2
diabetes. As a second part of the study it was planned to
investigate whether the major GLUT isoforms
(GLUT1, GLUT3) are involved in the transport of glu-
cose across the lymphocyte plasma membrane.
MATERIALS AND METHODS
Patients
The study group included 60 patients with type 2
diabetes and 30 age-, weight-, and sex-matched healthy
subjects serving as a control group. The clinical diagno-
sis of type 2 diabetes was made according to World
Health Organization criteria, and all such consenting
patients were enrolled, excluding those with any diabet-
ic complications. None of the patients or healthy sub-
jects had impaired renal function (serum creatinine
concentrations >130 µmol/l and no microalbuminuria),
hypertension (sitting office blood pressure of more
than 140/90 mmHg on two occasions), hypercholes-
terolemia (total cholesterol >5.0 mmol/l), proliferative
retinopathy, or impaired liver function. The diabetic
patients were classified into two subgroups according to
the mode of therapy. Thirty patients were treated with
diet only and 30 patients were treated with diet and
insulin (mean daily dose: 46.0±5.0 IU). As the control
group, 30 healthy subjects with no family history of type
2 diabetes were enrolled. None of the healthy subjects
had been treated with any drugs during the investiga-
tion and three months before. All the patients and
healthy subjects were informed about the aim of the
study and agreed to comply with all study requirements
by giving their written informed consent. The investiga-
tions were carried out in accordance with the principles
of the Declaration of Helsinki. The institutional review
board of Warsaw Medical University approved the 
protocol.
Lymphocyte isolation
An overnight-fasted blood sample (5 ml) was drawn
from the antecubital vein and collected into
a heparinized tube. Lymphocytes were isolated within 2
h from venipuncture by density gradient centrifugation
in Gradisol L (Aqua-Medica, Poland; 1200×g, 20 min).
Afterwards the lymphocytes were collected and washed
twice with 0.9% NaCl solution (500×g, 10 min). After
isolation, the lymphocytes were washed twice in the
transport solution (20 mM Hepes, 150 mM NaCI, 5 mM
KCI, 5 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 2
mM pyruvate, pH 7.4) [6] and an adequate volume of
transport solution was added to obtain a density of 106
cells/ml. Such a suspension was used for the inves-
tigation.
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Lymphocyte viability was determined using vital dye
exclusion. Cells were incubated in transport solution
with deoxy-D-glucose. After 60 min, a 1% solution of
trypan blue (1:1 vol) was added to the cell suspension
and living lymphocytes were counted under a light
microscope.
Immunocytochemistry
This test was carried out according to a modified
method described by Maher et al. [24] to reveal the
presence of GLUT proteins. Commercial antibodies
obtained from Chemicon International Inc. (CA,
USA), were used. The primary antibodies were poly-
clonal rabbit anti-GLUT1 antibodies against the C-ter-
minus of rat GLUT1 and anti-GLUT3 antibody against
the C-terminus of mouse GLUT3. Horseradish peroxi-
dase-conjugated anti-rabbit IgG was used as a sec-
ondary antibody.
Slides with lymphocytes were incubated with 3%
hydrogen peroxide for 5 min at room temperature to
inhibit endogenous peroxidase. Then the cells were
washed with phosphate buffered saline (PBS) and
blocked with 1% bovine serum albumin (BSA) diluted
in PBS. Fixed lymphocytes were treated with rabbit anti-
GLUT (1:200) for 30 min at room temperature, washed
three times with 1% BSA, and incubated with secondary
antibody (1:2000) for 30 min at room temperature.
Antibody-antigen complexes were visualized by 3,3-
-diaminobenzidine (DAB; Sigma, USA) according to
the instructions of manufacturer. After this procedure,
the slides were washed with distilled water, dehydrated
through a series of graded ethanol solutions, xylene fol-
lowed by the addition of D.P.X (neutral mounting medi-
um; Aldrich, USA). For a negative control, the cells
were incubated without primary antibodies for 30 min at
room temperature.
Western blot analysis
Western blot analysis was carried out to confirm the
results of immunocytochemistry. For protein expression
of GLUT1 and GLUT3, an aliquot (60 µg) of cell
extract was re-suspended in Laemli buffer with β-mer-
captoethanol and heated (90°C) for 5 min. Proteins
were separated by SDS-PAGE, transferred to nitrocel-
lulose membranes, and blocked by 5% milk in TBS (20
mM trisma, 500 mM NaCl, pH=7.6) for 12 h at 4°C. The
membranes were incubated with the primary anti-
GLUT1 and anti-GLUT3 rabbit polyclonal antibodies
(Chemicon, USA). Then the membranes were washed
and incubated with secondary horseradish-conjugated
goat anti-rabbit IgG antibody (Chemicon, USA).
Following incubation with the secondary antibody, the
membranes were washed and antibody-antigen com-
plexes were visualized by DAB (Sigma, USA) according
to the instructions of the manufacturer.
Deoxy-D-glucose uptake by lymphocytes
The experiment was carried out according to a part-
ly modified method described by Kaliman et al. [19]. To
290  µl (3×105 cells) of cell suspension the 1.5 µl of
deoxy-D-glucose, 2-[3H(G)] (7.70000 Cii/mmol) and 7.5
µl of PBS were added. In line with results obtained ear-
lier [34], the times of lymphocyte incubation with deoxy-
-D-glucose were established as 15, 30, or 60 min. At
these time points, the transport was stopped by addition
of 2 vol of ice-cold 50 mM glucose in PBS. Then deoxy-
-D-glucose was washed away using the same solution
and the cells were lysed with 0.1 M NaOH/0.1% SDS.
After lysis of the cells (within 24 h), the radioactivity in
curie count per minute (ccpm) was determined by
a scintillation counter. Each condition was run in tripli-
cate. Non-specific uptake (t=0) was determined by
incubating the lymphocytes with radiolabeled glucose in
the stop solution (50 mM glucose in PBS) instead of
transport solution.
The statistical analysis
The results were compared using the Wilcoxon test
[1] at confidence levels of 99 and 95% (p=0.01 and
p=0.05). Results were expressed as mean ±SD.
RESULTS
The clinical characteristics of the control and diabet-
ic subjects are summarized in Table 1.
Viability test
The procedures applied did not have any influence
on the survival rate of lymphocytes (as assessed by the
trypan blue vital test). There were no differences in the
numbers of dead cells in the lymphocyte populations
from healthy subjects and from both diabetic patients
groups, and total cell viability was approximately 95%.
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Table 1. Subjects’ characteristics (mean (SD))
Control   Diabetic patients
group diet insulin
Number 30 30 30
Sex (M/F) 15/15 15/15 15/15
Age (years) 63.8 (2.6) 63.9 (3.1) 65.2 (2.5)
BMI (kg/m2) 24.1 (1.0) 24.5 (1.6) 25.0 (1.1)
Duration of diabetes  0 2.5 (1.0) 7.3 (2.7)
(years)
Insulin dose ( IU/24 h) 0 0 46.0 (5.0)
Fasting glycemia  4.9 (0.3) 6.0 (0.7) 6.3 (0.6)
(mmol/l)
HbA1C(%) 4.9 (0.6) 6.6 (0.7) 7.0 (0.5)
Total cholesterol  4.2 (0.5) 5.2 (0.6) 5.1 (0.4)
(mmol/l)
Triglycerides (mmol/l) 1.4 (0.2) 1.8 (0.3) 1.7 (0.3)Immunocytochemistry
Immunocytochemistry showed the presence of the
specific transport proteins GLUT1 and GLUT3 in the
investigated lymphocytes. In the control sample (with-
out the first antibody), the reaction was negative.
Immunocytochemical reactions with antibodies against
GLUT1 and GLUT3 were positive in lymphocytes in
both groups of diabetic patients and in the control group
(Fig. 1–3). Staining was more intensive for GLUT3 than
for GLUT1 in all the groups under study. The intensities
of the reactions for GLUT1 and GLUT3 were similar in
all the investigated groups. 
Western blot analysis
The results of Western blot analysis revealed two
bands, characteristic of GLUT1 (49 kDa) and of
GLUT3 (45 kDa). The band characteristic of GLUT3
was stronger than the band of GLUT1 (Fig. 4).
Deoxy-D-glucose uptake by lymphocytes
Deoxy-D-glucose uptake values are presented as
ccpm. In order to evaluate the kinetics of the process,
the results at 30 and 60 min are presented as a multiples
of the respective 15-min value. During the experiment,
a gradual increase in deoxy-D-glucose uptake was
observed in healthy subjects. Mean ccpm values in this
group at 15, 30, and 60 min were 5110, 10660.63, and
19667.73, respectively. These values present an almost
linear dynamics of deoxy-D-glucose uptake. At 30 min
the ccpm value increased 2.09-fold and at 60 min 3.85-
-fold in comparison with the 15-min value.
In diabetic patients, deoxy-D-glucose uptake also
increased over time, but the values and dynamics of the
process were different from those observed in the healthy
population. In the diet-treated diabetic group, the deoxy-
-D-glucose uptake value at 15 min was 7026.03 ccpm. At 30
min the value was 7176.80 ccpm, increasing only 1.02-fold.
At 60 min, deoxy-D-glucose uptake reached 10886.77
ccpm, a value 1.55-fold greater than at 15 min. There was
a statistically significant difference in results between the
diet-treated group vs. the control group (Fig. 5).
In the insulin-treated diabetic group, glucose trans-
port presented different characteristics. Values of
deoxy-D-glucose uptake were very high. At 15 min it
was 10748.23 ccpm, at 30 min 23150.77 ccpm, and at 60
min 25141.13 ccpm. When compared with the 15-min
value, the values increased 2.15-fold at 30 min and only
2.34-fold at 60 min. There was a statistically significant
difference in the results between the insulin-treated
group vs. the control group (Fig. 6).
DISCUSSION
Diabetic patients cannot be regarded as a homoge-
nous population when considering lymphocyte function.
Glucose transport into lymphocytes in both of the dia-
betic subject groups studied, has its distinct characteris-
tics. Patients treated with diet represent a population in
the early phase of the disease. It can be expected that
cellular glucose transport at this stage of diabetes is not
significantly changed. Some studies show that in type 1
diabetes, 2-deoxy-D-glucose uptake does not correlate
with duration of the disease [7]. These findings cannot
be applied to type 2 diabetes directly, but give an idea of
alterations in the process of glucose transport in
patients with pathological glucose metabolism. 
Fig. 1. Immunocytochemical detection of GLUT1 and GLUT3
proteins in lymphocytes from healthy subjects.
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Control
GLUT1
GLUT3In our study, the deoxy-D-glucose transport into
lymphocytes of diet-treated patients was altered. In the
diet-treated group at 15 min, the values of deoxy-D-glu-
cose uptake were higher than in the control group,
which is a feature characteristic of all diabetic patients.
Surprisingly, at 30 and 60 min of observation, the uptake
values in the diet-treated group were lower, increasing
slowly with time. This indicates that glucose transport in
this group is delayed in time, which is an important
alteration occurring early in diabetes. The insulin-treat-
ed group represents a population of diabetic patients at
a more advanced stage of the disease. Very high values
of deoxy-D-glucose uptake were observed at all times,
but especially at the beginning of the experiment. At 15
min the ccpm value was more than 2-fold the value
noted in the control group and more than the value in
the diet-treated group (Fig. 7). These differences were
still present at 30 and 60 min of observation. The values
at 30 min had increase 2-fold, i.e. similar to the situation
in the control group but at a much higher level. Later
there is a drop in glucose uptake, and at 60 min
a plateau phase was observed. 
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Fig. 2. Immunocytochemical detection of GLUT1 and GLUT3
proteins in lymphocytes from diet treated diabetic patients.
Control
GLUT1
GLUT3
Fig. 3. Immunocytochemical detection of GLUT1 and GLUT3
proteins in lymphocytes from insulin treated diabetic patients.
Control
GLUT1
GLUT3The differences between the diabetic patient groups
may depend on the mode of therapy and also result
from the metabolic changes developing during the pro-
gression of diabetes. In the case of patients treated with
diet, it is possible that these differences are caused by
the disease only. There are other factors, such as diet
content [22] and physical activity, that influence glucose
metabolism in the course of chronic conditions. It has
been shown that exercise stimulates both glucose uptake
and glycogen synthesis. These investigations were car-
ried out in human muscles [8, 14], with the focus on
GLUT proteins. Lymphocyte studies concerning the
influence of exercise on glucose transport in humans are
not reported. However, in rats, a stimulation of GLUT1
expression in splenic lymphocytes has been observed
after exercise [3]. In patients treated with insulin, alter-
ations in glucose transport may result from both the dis-
ease itself and the mode of therapy. Insulin is the most
potent medication that influences glucose metabolism.
Glucose transport into cells increases in the presence of
insulin. In cultured 3T3-L1 adipocytes, insulin rapidly
stimulates glucose movement into cells. The observed
transport rate was over 10-fold higher than in the con-
trol group. The investigations revealed that GLUT1 has
an important part in this process [3].
Results published by other authors [7, 11] on the
influence of insulin on deoxy-D-glucose uptake by lym-
phocytes differ from the outcomes of our study. Those
authors reported that insulin stimulated glucose uptake
only in monocytes, whereas it did not have any influence
on lymphocytes. These studies involved patients with
type 1 diabetes, who in many aspects differ from type 2
diabetic patients. Autoimmune reactions that are
believed to play a major role in the pathogenesis of type
1 diabetes may have a great impact on lymphocyte func-
tions. Moreover, type 1 diabetic patients develop vascu-
lar complications earlier and more frequently. We
excluded patients from our study with vascular compli-
cations of diabetes, who are certainly a population at the
most advanced stage of the disease. In our research, we
investigated the transport of glucose in patients treated
with insulin, but did not add insulin to the isolated lym-
phocyte samples. In contrast, other investigators added
insulin to already isolated blood cells.
The immunocytochemical method and Western blot
analysis showed the presence of glucotransporters
GLUT1 and GLUT3 in the investigated lymphocytes.
These proteins have been considered major glucotrans-
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Fig. 4. Western blot analysis of representative samples: P1 – healthy
subject, P2 – diet treated diabetic patient, P3 – insulin treated dia-
betic patient. The results of Western blot analysis revealed two
bands, characteristic of GLUT1 (49 kDa) and of GLUT3 (45 kDa).
Fig. 5. Deoxy-D-glucose uptake (a) and its dynamics (b) in lym-
phocytes of healthy subjects and diet treated patients. Differences
in deoxy-D-glucose uptake between diet treated patients and con-
trol group were statistically significant (p=0.01) at 15, 30 and 60
min of the observation (a). Increase in deoxy-D-glucose uptake is
gradual in healthy subjects with almost linear dynamic (b). In diet
treated patients increase in transport rate is delayed.
Deoxy−D−glucose uptake in
lymphocytes in diet group vs. control
group. Mean values at 15, 30 and 60
minute of observation.
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Fig. 6. Deoxy-D-glucose uptake (a) and its dynamics (b) in lym-
phocytes of healthy subjects and insulin treated patients.
Differences in deoxy-D-glucose uptake between insulin treated
patients and control group were statistically significant at 15, 30
(p=0.01) and 60 (p=0.05) minutes of the observation (a).
Slowdown of deoxy-D-glucose uptake at 60 min is characteristic of
insulin treated patients (b).
Deoxy−D−glucose uptake in
lymphocytes in insulin group vs.
control group. Mean values at 15, 30
and 60 minute of observation.
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(a) (b)porters in these blood cells. We found a very strong effect
of insulin on deoxy-D-glucose uptake in peripheral blood
lymphocytes. Although we have not found the existence of
other glucotransporters in human peripheral blood lym-
phocytes in available literature, these results suggest the
expression of an insulin-sensitive glucose transporter in
these cells. These findings are consistent with published
data on GLUT expression in the leukocytes of healthy
subjects, but not in lymphocytes where GLUT proteins
were found only in small amounts [21]. It was also shown
that monocytes expressed GLUT1 protein in type 1 dia-
betes [7]. Information regarding GLUT expression in
leukocytes in type 2 diabetic patients is scarce. 
In conclusion, the results of our study show that glu-
cose transport in lymphocytes is profoundly altered in
type 2 diabetes. There are statistically significant differ-
ences in glucose uptake between each of the diabetic
patients groups in comparison with healthy subjects.
This phenomenon could reflect the adaptation of
immunocompetent cells to the abnormal metabolic con-
ditions (hyperglycemia, etc.) typical of diabetes. There
was also a significant difference between the groups of
patients treated with different modes of therapy.
Treatment, however, does not normalize altered lym-
phocyte glucose transport function. Insulin therapy
stimulates glucose uptake, but it is difficult to determine
if this is advantageous for lymphocyte functions. High
glucose concentrations in cytoplasm may be toxic as
well. The investigated groups represent patients at dif-
ferent stages of the disease: patients at an early stage
who require diet only in order to maintain glycemia
within the accepted range and patients at advanced
stage who require insulin. Glucose transport properties
distinctly change with the progression of diabetes. 
Peripheral blood lymphocytes are particularly vulnera-
ble to alterations in blood glucose levels. The major gluco-
transporters are expressed on these cells. Blood cells such
as lymphocytes are much more easily available for studies
in humans than muscle or adipose tissue. Lymphocytes are
easily obtainable and retain viability during in vitro cultur-
ing (in contrast to granulocytes, which are fragile, and
monocytes, which are scarce and difficult to isolate).
Therefore, these cells may become a convenient model for
studies of the influence of diabetes on glucose utilization in
human subjects. In conclusion, we postulate that peripher-
al blood lymphocytes should be considered as a promising
tool in the field of glucose transport investigations.
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